Experts say supplement companies have tried to capitalize on the GLP-1 craze, putting the phrase in their product names, ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Experts warn that the surge in demand for weight loss injections like Ozempic and Wegovy is unsustainable, with most users ...

Explore the potential of GLP-1 receptor agonists for rheumatoid arthritis. Learn about their safety, benefits, and what to consider before starting these medications.

Researchers analyzed nearly 60,000 public Facebook posts to identify real-world adverse events linked to GLP-1 receptor ...

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that the first participants with obesity or overweight with at least one weight-related comorbidity have been dosed in its U.S. 12-week ...

Detailed price information for Lexaria Bioscience Corp (LEXX-Q) from The Globe and Mail including charting and trades.

Researchers conducted the ACHIEVE-1 trial to assess the effect of orfoglipron on glycemic control among patients with early-stage type 2 diabetes.

DehydraTECH-semaglutide reduces overall side effects by 36.5% as compared to Rybelsus®DehydraTECH-semaglutide reduces gastrointestinal side effects by 43.5% as compared to Rybelsus®DehydraTECH-GLP-1 s ...

CBL-514, Caliway's first-in-class lipolysis drug candidate, has been granted clearance from the U.S. FDA to proceed with SUPREME-01, a global, ...

These five upcoming data drops could usher in more effective and convenient therapies for Alzheimer’s disease and open up ...

CagriSema vs placebo was associated with significant weight loss among adults with overweight or obesity with or without type 2 diabetes.